These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38157645)

  • 1. Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment.
    Wang Y; Cheng W; Zhu J; He L; Ren W; Bao D; Piao JG
    Biomed Pharmacother; 2024 Jan; 170():116084. PubMed ID: 38157645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
    Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
    ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
    Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
    Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles.
    Zhu Z; Li Y; Yang X; Pan W; Pan H
    Pharmacol Res; 2017 Dec; 126():84-96. PubMed ID: 28734999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
    Patel K; Chowdhury N; Doddapaneni R; Boakye CHA; Godugu C; Singh M
    J Pharm Sci; 2015 Dec; 104(12):4417-4426. PubMed ID: 26372815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
    He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
    J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Antitumor Efficacy of a Dextran-based Docetaxel-coupled Conjugate against Triple-Negative Breast Cancer.
    Lv H; Jia W; Dong P; Liu J; Wang S; Li X; Hu J; Zhao L; Shi Y
    Curr Drug Deliv; 2024; 21(5):775-784. PubMed ID: 37349996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer.
    Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C
    J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of Docetaxel and Disulfonate Tetraphenyl Chlorin in One Nanoparticle Produces Strong Synergism between Chemo- and Photodynamic Therapy in Drug-Sensitive and -Resistant Cancer Cells.
    Gaio E; Conte C; Esposito D; Miotto G; Quaglia F; Moret F; Reddi E
    Mol Pharm; 2018 Oct; 15(10):4599-4611. PubMed ID: 30148955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer.
    Palma G; Conte C; Barbieri A; Bimonte S; Luciano A; Rea D; Ungaro F; Tirino P; Quaglia F; Arra C
    Int J Pharm; 2014 Oct; 473(1-2):55-63. PubMed ID: 24992317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Synergism Mechanism of Tamoxifen and Docetaxel by Nanoparticles.
    Zhu Z; Pan H; Li Y; Pan W
    Anticancer Agents Med Chem; 2019; 19(16):1991-2000. PubMed ID: 31267877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
    Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
    Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
    Doddapaneni R; Patel K; Chowdhury N; Singh M
    Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
    Chen R; Ni S; Chen W; Liu M; Feng J; Hu K
    Int J Nanomedicine; 2021; 16():5265-5279. PubMed ID: 34376979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer.
    Paiva KLR; Radicchi MA; Báo SN
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer.
    Xu Y; Wang C; Ding Y; Wang Y; Liu K; Tian Y; Gao M; Li Z; Zhang J; Li L
    J Biomed Nanotechnol; 2016 Sep; 12(9):1774-81. PubMed ID: 29345888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient in vitro and in vivo docetaxel delivery mediated by pH-sensitive LPHNPs for effective breast cancer therapy.
    Jadon RS; Sharma G; Garg NK; Tandel N; Gajbhiye KR; Salve R; Gajbhiye V; Sharma U; Katare OP; Sharma M; Tyagi RK
    Colloids Surf B Biointerfaces; 2021 Jul; 203():111760. PubMed ID: 33872827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB.
    Zhu J; Zhang Y; Chen X; Zhang Y; Zhang K; Zheng H; Wei Y; Zheng H; Zhu J; Wu F; Piao JG; Zhu Z; Li F
    Biochem Biophys Res Commun; 2021 Jan; 534():902-907. PubMed ID: 33162028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.